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NMR were increased to improve accuracy and achieve better readings from the data.    In 
summary, the data showed that ketamine produces a change in brain phospholipid levels in a 
pattern that is consistent with that seen in human schizophrenia.      
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 Schizophrenia is a pervasive mental disorder than greatly reduces the quality of life of the sufferers.  
Ketamine is an anesthetic and a NMDA receptor antagonist.  The “high” from abusing ketamine results in a 
dissociative state that closely resembles many of the symptoms of schizophrenia.  Many researchers are using 
ketamine to “induce” the behavioral symptoms of schizophrenia in order to better study the disease.  Through this 
research I am attempting to validate whether the ketamine model of schizophrenia also models the 
neurochemistry of the disorder that is critical for use in the development of new drug interventions.  Recently 
scientists have discovered that levels of certain phospholipids present in the brain are reduced in those with the 
disease.  The animals in this research were dosed with ketamine and brain samples were then obtained at + 20 
minutes, 24 h, and 48 h post-injection.  An untreated control was also completed.  Brains were removed and 
homogenized in hexane-isopropanol followed by centrifugation at 2500 x g.  The hexane-isopropanol was removed 
under nitrogen and Cs-EDTA and CDCl3-CH3OH were added to the final product.  31P NMR was then performed to 
determine the levels of phospholipids.  The initial results showed similarities to that of the published literature 
from patients with schizophrenia.  However, we were able to improve results with an additional step of 
sonification that was performed prior to centrifuging.  Additionally, the number of cycles of the 31P NMR were 
increased to improve accuracy and achieve better readings from the data.    In summary, the data showed that 
ketamine produces a change in brain phospholipid levels in a pattern that is consistent with that seen in human 
schizophrenia.  
Introduction: 
Ketamine is a drug commonly used in the medical community as an anesthetic (Bergman 1999).  Ketamine 
is most often utilized in the form of a hydrochloride salt and is a potent NMDA receptor antagonist.  Ketamine has 
a high potential for abuse and addiction due to the calming and dissociative state achieved after ingestion.  The 
“high” obtained from ketamine can be compared to that of using dextromethorphan (DXM) and phencyclidine 
(PCP)(Bergman 1999).  Ketamine has a redistribution half-life of 4.68 minutes and an elimination half-life of 2.17 
hours (Bergman 1999).  At higher doses users may experience what is referred to as the “K-hole”.  This “K-hole” of 
dissociation closely imitates the mental health disease schizophrenia.    
Schizophrenia is a debilitating mental health disorder. While the specific causes of schizophrenia are 
unknown, current research is providing more insight and understanding to the possible causes for developing the 
disease.  Scientists currently understand that there are several possible factors that can contribute to the disease; 
environmental factors (socioeconomic status, sexual orientation, complications at birth and use of marijuana), 
genetic susceptibility and lateralization of dopaminergic receptors and increased dopaminergic activity in those 
diagnosed with schizophrenia (Keshavan, et al, 2008).  While schizophrenia remains to be an incurable disease, 
physicians and psychotherapists have a large arsenal of methods to increase the quality of life for the individual.   
Through the use of animal models, a state of ketamine induced psychosis or the “k-hole” will be achieved 
through administration of the drug.  The animals will then be analyzed using laboratory techniques.  The 
techniques used will analyze levels of phospholipids present in the brain using 31P analysis.  These test animals will 
then be compared to a control group to determine notable differences. 
 
Experimental: 
 The mice used in the experiment were C57BL/6J from Jax Industries; the mice were housed in standard 
conditions with continuous access to food and water.  The ketamine used was pharmaceutical grade ketamine.  
The dosing schedule include the following; group 1 dosing at 48 and 24 hours, group 2 dosing at 24 hours, group 3 
dosing at 20 minutes, and group for was the control group (time indicates dosing prior to the time of sacrificing.  
 After sacrificing the brains are removed and mixed with hexane-isopropanol (3:2) at a volume of 18;1 
ratio and manually homogenized for 10 minutes.  The homogenate is centrifuged at 2500xg for 10 minutes at 8 ˚C, 
the supernatants are then removed and stored.  The hexane-isopropanol removed via nitrogen stream and 0.94 
mL of CDCl3:CH3OH (10:4) and 134 μL 0.2 M Cs-EDTA at pH 6.0 are added to the final product.  The solution is left 
to settle the phases and the aqueous phase is discarded.  The remaining organic phase is transferred to an NMR 
tube and analyzed via 31P NMR. 
Results/Discussion: 
 The results indicated that the solutions prepared had very low concentrations of phosophlipids present.  
The resulting 31P NMR spectra (see figures 1-4 in the appendix) indicated a cluster of peaks around the 1.00 to -
1.00 PPM area which is similar to that of the literature expected results (figures 9-10).  A peak of 
phosphatidylcholine was identified at roughly -.1352 PPM on each spectrum which matched that of the 
phosphatidylcholine standard run previously.  The peaks displayed on figures 1,2 and 4 at 116 and 117 PPM 
remained to be unidentified as well as the peak around -27 PPM on figure 4.  A second trial was run with the 
addition of the sonication step and provided much better clarity from the NMR spectra.  The new NMR data 
analyzed was determined to have PC and PE peaks. 
Conclusion: 
Previous studies have shown that ketamine induces a pattern of behaviors that is consistent with those 
seen in schizophrenia.  This study suggests that ketamine induces a change in brain total phospholipid levels that 
parallel those seen in schizophrenia.  Furthermore we found that phosphatidylcholine levels increased at all-time 
points tested compared to untreated controls with the highest increase seen at the 48 h time point.  An increase in  
phosphatidylcholine levels  indicates that apoptosis (programmed cell death) is occurring as is presumed to occur 
in human schizophrenia leading to a reduction in the size of structures such as the hippocampus.   These results 
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Figure 1: 31P NMR spectra of Subject A 
 
Figure 2: 31P NMR spectra of Subject B 
 
Figure 3: 31P NMR spectra of Subject C 
 
Figure 4: 31P NMR spectra of Subject D 
 
Table 1: Peak Locations for figures 1-4 
 
Peak Location (PPM) 
1 2 3 3 
117.01 117.32 - 117.21 
116.53 116.21 - 116.41 
.81 .84 .74 .93 
-.14 -.15 -.12 -.14 
- -12.21 -12.42 -12.53 
- - -27.82 - 
 
Figure 5: 31P NMR spectra of Subject E  
 

















Figure 10: 31P NMR spectra of Subject J 
 




Figure 12: 31P NMR spectra of Subject L 
 
 
















Table 2: Phospholipid Integral Values E-F 
Subject PC Unknown PI PS PE1 PE2 Unknown Unknown Total 
E 1.05 
   
1.49 





   
2 
G 0.85 
   
1.3 





   
2.19 
I 2.25 0.23 0.15 3.23 3.23 
 
0.15 0.12 6.21 
J 2.27 0.3 0.1 3.34 3.34 3.34 0.25 0.13 6.44 
K 2.75 0.14 0.23 3.93 3.93 
 
0.24 0.14 7.33 







0.11 0.97 2.46 
 
0.15 0.13 5.69 
N 2.2 
 
0.26 1.22 2.62 2.62 0.22 0.16 6.29 
O 2.14 0.17 0.34 1.27 2.44 2.44 0.13 0.13 6.25 
P 2.61 0.21 0.19 1.42 2.62 2.62 0.18 0.13 7.44 
 
Figure 17: Phospholipids 
PC – Phosphatidylcholine 
PI – Phosphatidyinositol  
PS – Phosphatidylserine 
PE1 – Phosphatidylethanolamine 
PE2 – Phosphatidylethanolamine 
 
Table 3: Peak Locations E-F (PPM) 
 
Subject Peak Locations (PPM) 
E -0.2163 0.6217 
      
F -0.2271 0.4866 0.6799 
     
G -0.2703 0.5557 
      
H -0.1892 0.5947 0.7569 
     
I -0.3321 -0.027 0.1604 0.3784 0.4866 0.7056 0.8387 
 
J -0.2899 -0.027 0.1898 0.4055 0.4863 0.5406 0.7353 0.8642 
K -0.2703 0 0.1861 0.4325 0.5677 0.7537 0.8684 
 
L -0.3029 0.1892 0.5136 0.7298 
    
M -0.2973 0.1806 0.4055 0.4866 0.7232 0.871 
  
N -0.2973 0.1683 0.4055 0.4595 0.5104 0.7288 0.8597 
 
O -0.2973 0.027 0.1642 0.3766 0.4595 0.5109 0.7285 0.865 





















PC  – phosphatidylcholine 
PCaa  – alkyl, acylphosphatidylcholine 
U3 – Unidentified 
PI  – phosphatidylinositol 
PS – phosphatidylserine 
SM  – sphingomyelin 
PE  – phosphatidylethanolamine 
Pep  – phosphatidylethanolamine plasmalogen 
Peaa  – alkyl, acyl-phosphatidylethanolamine 
U2  – Unidentified 
U1 – Unidentified 
LPE  – lysophosphatidylethanolamine 
Figure 10: 31P NMR spectra of rat brain (control) 
 
 
Figure 11: 31P NMR spectra of rat brain (ischemic  
 






1 – ethanolamine lysophospholipids 
2 – cardiolipin 
3 – 1,2-diacyl-sn-glycero-3-phospho-(N-acyl)-ethanolamine 
4 – 1-(1’-alkenyl)-2-acyl-sn-glycero-3-phospho-(N-acyl)-ethanolamine 
5 – 1-alkyl-2-acyl-sn-glycero-3-phosphoethanolamine 
6 – 1-(1’-alkenyl)-2-acylsn-glycero-3-phosphoethanolamine 
7 – 1-alkyl-2-acyl-sn-glycero-3-phosphoethanolamine 
8 – phosphatidylserine 
9 – sphingomyelin 
10 – phosphatidylinositol 
11 –  choline phospholipids 
12 –  Unknown 
13 – 1-alkyl-2-acyl-sn-glycero-3-phosphoethanolamine 
14 – 1,2-diacyl-sn-glycero-3-phosphocholine 
